TD Cowen initiated coverage of Upstream Bio (UPB) with a Buy rating. The firm says the company’s verekitug is a “differentiated fast follower” with greater potency and extended dosing intervals versus Tezspire. Tge Phase 1 data have shown “rapid, deep, and sustained effects” on asthma biomarkers, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB: